# Optimal Application Timing of ADC Drugs for Advanced Breast Cancer

> **NCT07657130** · PHASE2 · RECRUITING · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer Females

## Interventions

- **DRUG:** Antibody drug conjugate
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07657130
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07657130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07657130, "Optimal Application Timing of ADC Drugs for Advanced Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07657130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*